Abstract | Alzheimer disease (AD) is one of several neurodegenerative diseases characterized by dysregulation, misfolding and accumulation of specific proteins in the CNS. The stable isotope labelling kinetics (SILK) technique is based on generating amino acids labelled with naturally occurring stable (that is, nonradioactive) isotopes of carbon and/or nitrogen. These labelled amino acids can then be incorporated into proteins, enabling rates of protein production and clearance to be determined in vivo and in vitro without the use of radioactive or chemical labels. Over the past decade, SILK studies have been used to determine the turnover of key pathogenic proteins amyloid-β (Aβ), tau and superoxide dismutase 1 (SOD1) in the cerebrospinal fluid of healthy individuals, patients with AD and those with other neurodegenerative diseases. These studies led to the identification of several factors that alter the production and/or clearance of these proteins, including age, sleep and disease-causing genetic mutations. SILK studies have also been used to measure Aβ turnover in blood and within brain tissue. SILK studies offer the potential to elucidate the mechanisms underlying various neurodegenerative disease mechanisms, including neuroinflammation and synaptic dysfunction, and to demonstrate target engagement of novel disease-modifying therapies.
The accumulation of misfolded proteins in the CNS is a pathogenetic mechanism shared by several neurodegenerative diseases, including Alzheimer disease (AD), Parkinson disease and some forms of dementia. Understanding the mechanisms and rates of production and clearance for specific proteins associated with these diseases will be important to understand how such a state of disequilibrium arises and to identify the factors that influence it.
Naturally occurring stable isotopes of chemical elements, such as 13 C, 15 N and 2 H, have been used to interrogate human physiology and pathophysiology since basis of their mass difference. As these 'heavy' isotopes do occur in nature, albeit at very low concentrations, all organic molecules will demonstrate a background level of incorporation that must be considered in the analysis.
Amino acids labelled with stable isotopes can be administered to humans either intravenously or orally, becoming incorporated into (and thereby labelling) newly translated proteins. These labelled proteins are harvested from blood, cerebrospinal fluid (CSF) and/or tissue samples and are typically enriched by immunoprecipitation before being digested using enzymes such as trypsin, LysN or AspN proteases. The ratio of labelled to nonlabelled peptide, which can be quantified using targeted MS, reflects the rate of labelled amino acid incorporation into the protein. Thus, SILK studies can provide dynamic measures of protein synthesis, protein release into body fluids or tissue and protein clearance. Furthermore, SILK has the potential to provide immediate in vivo evidence of target engagement in clinical trials, thereby advancing therapeutic discovery.
Alternative ways to measure protein turnover (for example, using radioactive isotopes such as 35 S-methionine) have been used to determine protein kinetics in in vitro systems. However, radioactive isotopes have limited use in humans, create substantial laboratory overheads when used for in vitro studies and (unlike SILK) cannot provide highly specific and precise turnover data on individual proteins. Proteins can also be chemically tagged with a variety of optical and other molecules for tracking turnover and transport 2 . These systems are widely used in vitro; however, they all have limited applicability in humans or animal models, and the label itself can also potentially influence protein kinetics. By contrast, SILK studies essentially label proteins subatomically (that is, with additional neutrons), which avoids the risk of artefactually altering protein kinetics. The SILK technique has been proved safe in animal and human studies.
In this Perspectives article, we discuss the principles of SILK, summarize the results of key studies in which SILK provided insights into neurodegenerative disease and discuss its utility across clinical and preclinical models of these diseases. their discovery in the 1920s 1 . However, such isotopes have been employed to probe protein synthesis and clearance rates in the CNS in vivo and in vitro only during the past decade. The isotopes used in stable isotope labelling kinetics (SILK) studies possess additional neutrons in their atomic nuclei that make them fractionally heavier but nonradioactive. As these isotopes are chemically identical to the natural element, they participate in the same reactions and become incorporated into organic molecules such as proteins and DNA. Mass spectroscopy (MS) can be used to distinguish isotope-labelled compounds from their unlabelled counterparts on the SILK studies -capturing the turnover of proteins linked to neurodegenerative diseases Principles of SILK SILK has been used in preclinical model systems, including induced pluripotent stem cells (iPSCs), cell culture and animal models, as well as in humans, to measure protein synthesis and clearance rates (Fig. 1) . The SILK method involves administration of essential amino acids (that is, indispensable amino acids that cannot be synthesized by the body) enriched with naturally occurring stable isotopes; accordingly, the incorporation of these amino acids into newly synthesized proteins gradually increases until a steady state is reached. After administration of the labelled amino acid stops, the proportion of the labelled amino acid in the target protein gradually declines owing to protein clearance or degradation. Changes in the isotopic enrichment of the target protein enable the calculation of protein synthesis and clearance rates from the ratio of labelled (heavy) to nonlabelled (light) protein (Fig. 1) .
Leucine labelled with six 13 C atoms ( 13 C 6 -leucine) is the most widely used amino acid in SILK studies to date. C 6 -leucine. MS can then be applied to tissue or biofluid samples to identify and quantify these two forms. Kinetic models of the system are then used to estimate in vivo protein production, aggregation, transport and degradation rates.
By way of example, amyloid-β (Aβ) is produced primarily by neurons in the brain and is then secreted into the CSF 4 . As Aβ peptides in the CNS are continually being produced, degraded and cleared, the turnover of Aβ is the sum total of all the mechanisms underlying its accumulation, aggregation and removal. Irreversible deposition into amyloid plaques removes Aβ from the interstitial fluid (ISF), but not from the CNS. Aβ clearance from the CNS can occur via ISF or CSF transport, resorption 5 , transport across the blood-brain barrier 6 , reuptake by brain tissue, in situ proteolysis 7 and glymphatic clearance 8 . Through serial sampling of blood and CSF, SILK can be used to investigate these processes. When a stable isotope-labelled amino acid (tracer) is introduced, the isotopic enrichment (that is, the abundance) of heavy Aβ peptides increases over time as unlabelled peptides are replaced by newly synthesized, isotope-labelled peptides (Supplementary Movies 1-3). After tracer administration is discontinued, isotopic enrichment of the target protein or peptide gradually declines towards its natural (negligible) abundance. SILK can similarly be used to measure the kinetics of a variety of other important neuronal proteins, including tau, superoxide dismutase 1 (SOD1) and α-synuclein; as rates of protein synthesis and clearance differ, specific labelling protocols need to be established for each protein of interest.
Compartmental models can provide a mathematical framework that describes the flow of tracer from the administration site to the locus of protein synthesis and finally into the sampled tissue or fluid. In the case of Aβ, tracer is introduced into blood and incorporated into Aβ in the CNS and is sampled in CSF ( Fig. 2 C-leucine. To measure the turnover rate of a specific protein of interest, blood and cerebrospinal fluid (CSF) samples are collected at baseline and at appropriate intervals thereafter. Sampling intervals and duration are determined by the protein turnover rate. 13 C-Leucine levels in blood reflect tracer bioavailability , whereas 13 C-leucine levels in CSF and/or other body fluids reflect tracer incorporation into the target protein. To determine target protein kinetics, CSF samples usually undergo immunoprecipitation (to achieve target protein enrichment) and protease digestion, followed by label quantification using targeted mass spectroscopy (MS). These data are used to calculate the concentrations of labelled and unlabelled protein and, in compartmental modelling studies, to determine protein turnover rates.
of the predicted enrichment time course and curves are adjusted to optimize their fit to the observed SILK data. The labelling data are transformed by the model into a set of parameters that can be used to determine the effect of factors such as age 9 , sex, APOE4 genotype 10 , autosomal dominant AD (ADAD)-related mutation status 11 , drug treatment 12 , sleep 13 and amyloid deposition status 9 on Aβ kinetics.
Applying SILK to key proteins
In this section, we summarize the major findings from SILK experiments to date, focusing on proteins linked to neurodegenerative diseases.
Amyloid-β
In order to measure Aβ kinetics in the human CNS, a translational protocol was developed to label and track Aβ over a 36 h period during and after a 9 h intravenous infusion of 13 C 6 -leucine 9, 14, 15 . This protocol was then applied to SILK studies of individuals with ADAD 11 , sporadic AD and unaffected controls 9 to measure the turnover of three Aβ peptides -Aβ38, Aβ40 and Aβ42. A highly consistent finding in both ADAD and sporadic AD is that the turnover or clearance of soluble Aβ42 is specifically increased in individuals with amyloidosis, whereas Aβ38 and Aβ40 fractional turnover rates were unaltered by the presence of amyloidosis (Fig. 3) . Furthermore, the Aβ42:Aβ40 turnover rate ratio was positively correlated with the amyloid plaque load, as measured by Pittsburgh compound B PET (r = 0.45), and with the amyloid plaque growth rate (r = 0.75), suggesting that faster turnover of Aβ42 represents increased deposition of Aβ42 relative to Aβ40 in amyloid plaques 9, 11 . In addition, the Aβ42:Aβ40 production rate ratio was higher in PSEN mutation carriers than in non-carriers, which suggested that Aβ42 overproduction also contributes to ADAD. The turnover rates of all Aβ peptides slowed substantially with increasing age (half-lives for all peptides increased by 2.5-fold between the ages of 30 years and 80 years) 9 , which might account for the observed age-related increase in the risk of amyloid accumulation.
SILK studies of Aβ kinetics also enabled the mechanisms of action for proposed disease-modifying therapeutics to be investigated 16 . For example, treatment with γ-secretase and β-secretase 1 inhibitors resulted in a dose-dependent reduction in the accumulation of newly synthesized Aβ 12, 17 , without altering its clearance kinetics 12 . This observation implies that treatment with these agents reduces Aβ production, leading to reduced accumulation of Aβ. Moreover, SILK studies of plasma concentrations of Aβ in patients with sporadic AD and healthy control participants demonstrated that, in both groups, turnover of Aβ is about three times faster in plasma than in CSF 18 . Plasma Aβ42 and Aβ40 kinetics are virtually identical in individuals without amyloid deposition, whereas in amyloidpositive individuals (that is, those with substantial brain Aβ accumulation), fractional turnover of Aβ42 is faster than that of Aβ40. The same pattern was observed in CSF, albeit with a smaller magnitude of difference 18 . The findings of these plasma Aβ SILK studies led to the discovery that the plasma Aβ42:Aβ40 concentration ratio is a highly specific biomarker of brain amyloid plaques and elevated Aβ levels in CSF 18, 19 .
Effect of poor sleep on amyloid-β kinetics.
In both mouse and human studies, the concentration of Aβ in brain ISF and CSF oscillates with the sleep-wake cycle 20, 21 . Because Aβ deposition in the brain is concentration-dependent, prolonged bouts of wakefulness owing to sleep disturbances might increase the risk of AD via an Aβ-mediated mechanism 22 . To determine the kinetics underlying this Aβ oscillation, a SILK study found that the CSF concentration of Aβ increased by ~30% during sleep deprivation, although Aβ SILK curves in sleep-deprived individuals were similar to those of normal-sleep controls 13, 22 . In the SILK model, changes in Aβ production rate are directly proportional to CSF Aβ concentration, whereas the shape of the SILK curves is most sensitive to changes in Aβ clearance rates (Supplementary Movies 1,2). This observation suggests that volume 15 | JulY 2019 | 421 Nature reviews | NeuroLogy P e r s P e c t i v e s C-leucine curve (right). Mole fraction labelled (MFL) is a 'forcing function' that uses linear interpolation between measured time points to define tracer bioavailability for incorporation into target proteins. The compartmental model typically identifies a fractional turnover rate for the whole system, namely , the fraction of a rate-limiting compartment that is irreversibly removed per unit time. Mass flux rates along a pathway are calculated as the compartment mass multiplied by the rate constant. Specifically , if compartment 3 represents CSF Aβ, then the flux of Aβ through CSF (that is, the rate of appearance of Aβ into and disappearance of Aβ from CSF at steady state) is the product of the CSF concentration and k 03 . Compartmental modelling of stable isotope labelling kinetics (SILK) data consists of constructing a physiologically plausible model with optimized rate constants that provides an excellent fit to the experimental Aβ40 SILK data (solid line). In the CSF Aβ40 SILK data shown, gross systematic errors in the fit would result if k 03 is increased by 20% (dashed line).
changes in Aβ production underpin the sleep-mediated changes in Aβ concentration.
Amyloid-β SILK in human brain tissue.
The increased clearance of soluble Aβ42 from the CSF seen in individuals with amyloid deposition suggests that this protein is being incorporated into amyloid plaques 9 . SILK studies in combination with nanoscale secondary ion MS (NanoSIMS), collectively termed SILK-SIMS, has been used to image 13 C 6 -leucine in post-mortem brain sections from patients with AD 23 (Fig. 4) . This highresolution technique quantified the amount of labelled Aβ protein deposited in brain amyloid plaques in vivo during the interval between 13 C 6 -leucine administration and death (range 8 days to 4 years) 23 . The findings confirmed that labelled Aβ42 (and other Aβ proteins) is incorporated into plaques over the course of several days after label administration, indicating that plaques are dynamic structures that continue to sequester newly synthesized Aβ (that is, the Aβ produced during the labelling time window) rather than being fixed structures that remain unchanged in the brain for many years. Indeed, Aβ sequestration was shown to be a highly active process. This promising result, albeit obtained in a small number of participants, has led to the accelerated launch of a hospice study to measure plaque dynamics in human brains using SILK-SIMS. This technique has great potential to quantify the dynamics of other proteins in a range of neurodegenerative conditions. Apolipoprotein E SILK studies of apolipoprotein E (ApoE) turnover in plasma and CSF have been conducted to investigate the risk of AD conferred by different ApoE isoforms 10, [24] [25] [26] . All ApoE isoforms have similar turnover rates in CSF. In plasma, however, ApoE4 turnover is twofold faster than ApoE3 turnover, which is twofold faster than ApoE2 turnover 26 . SILK studies of brain homogenates from transgenic mice that express human APOE showed that clearance of ApoE, but not clearance of Aβ, was modulated by overexpression of LDLR (encoding the LDL receptor) and by knockout or overexpression of ABCA1 (encoding ATP-binding cassette A1) 25 . The Aβ synthesis rate in these mice was not modulated by expression of any human ApoE isoform 24 , which is consistent with SILK findings in humans that Aβ kinetics in CSF are not modified by ApoE isoforms 15 .
Superoxide dismutase 1
Heterozygous mutations in SOD1 are the cause of ~1-2% of amyotrophic lateral sclerosis (ALS) cases. SOD1 SILK studies can simultaneously quantify the turnover of both mutant and normal SOD1 in the same participant 27 . The motivation to develop this technology was driven by the recognition that SOD1 turnover rates might be particularly informative in the development of novel therapeutic strategies for ALS that focus on lowering levels of SOD1 mRNA. Improved understanding of SOD1 protein turnover in human CSF could inform the timing of CSF sampling in clinical trials of such agents and might improve estimation of the magnitude of the decrease in SOD1 levels.
SOD1 SILK requires a lengthy sampling protocol because the half-life of SOD1 in human CNS is ~25 days 27 . Studies of SOD1 turnover in CSF are ongoing in patients with ALS and known SOD1 mutations, patients with ALS without a known genetic cause and healthy controls. In mouse and rat models of ALS, SILK studies showed that measures of SOD1 synthesis responded earlier to treatment with RNA-lowering therapeutics than did the total concentration of SOD1 in CSF, suggesting that the changes in protein dynamics as measured by SILK might be promising early pharmacodynamic markers for RNA-targeted therapeutics 28 .
Tau
Along with amyloid plaques, tau aggregates (also known as neurofibrillary tangles) are a pathological hallmark of AD and other neurodegenerative diseases, collectively termed the tauopathies. Tauopathies are distinguished according to which tau isoforms are enriched in these aggregates, as differentiated by the number of repeats (R) in their microtubule-binding region: 3R in Pick disease, 4R in corticobasal degeneration and progressive supranuclear palsy and a mixture of 3R and 4R in AD tauopathies 29 . In addition to increased deposition of aggregated tau, patients with AD have increased CSF levels of total tau and specific phosphorylated tau (p-tau) species. Therefore, tau SILK studies were implemented to test the hypothesis that the increased CSF levels of tau and/or p-tau observed in these patients are due to changes in tau production or clearance rates.
Similarly to SOD1 SILK 27 , lengthy sampling protocols are required for SILK studies of tau, which has a CNS half-life of ~23 days 30 . To reduce the burden on study participants, 8 h, 16 h or 24 h intravenous infusion protocols were used and CSF samples were obtained at 4-5 follow-up visits scheduled over several months. Data from 24 participants with and without amyloidosis suggest that tau clearance is not altered by the presence of tau aggregates, as measured by 18 F-flortaucipir PET, although the tau production rate is doubled in the presence of amyloid deposition 30 . SILK studies have also been used to study tau kinetics in human iPSC-derived neurons. In vitro SILK studies offer several advantages over in vivo models, including increased label uptake, increased sampling frequency, ease of genetic and pharmacological intervention and access to intracellular compartments (Table 1) . In cell lysates, >15 tau peptides incorporate 13 C 6 -leucine, including 3R tau, 4R tau and p-tau. Tau truncation profiles found in iPSC-derived neurons and their culture media were similar to those found in brain and CSF, respectively. Despite this similarity, tau peptides measured in iPSC-derived neurons exhibited much shorter half-lives than those of the same peptides measured in human CSF (6 days versus 23 days). This observation could be explained by the complex interplay of multiple cell types in the CNS (including glia and different neuronal subtypes) and the effects of protein transport from the brain into CSF on tau kinetics. Other in vitro SILK studies also demonstrated that the release of full-length tau into the CSF occurred with no time delay, whereas truncated forms of tau were released into the CSF after 3 days. This observation adds to prior evidence for an active truncation and secretion mechanism for tau 27, 31 . Tau isoforms that are prone to aggregation might show increased turnover rates: 4R-tau isoforms and some types of p-tau exhibited faster turnover than 3R-tau isoforms or non-phosphorylated tau.
Tau SILK studies have considerable potential to advance our understanding of tau metabolism in health and disease and to provide tools for investigating the mechanisms of novel tau-targeted therapies 32 . These in vitro SILK studies might involve iPSC-derived neurons and other cell types derived from patients with mutations linked to AD and frontotemporal dementia, in combination with advanced cell culture systems (including transdifferentiation, organoids, long-term culture and co-culture) and genome-editing techniques 32 .
Potential applications of SILK
In this section, we consider potential practical advantages of SILK over techniques based on static biomarkers and hypothetical applications of SILK technology for probing specific aspects of neurodegeneration. Much work remains to be done as very few data currently exist about the turnover of the proteins mentioned in this section.
Kinetic versus static biomarkers
The concentration of a protein biomarker measured at a given time point in a biological fluid is an example of a static biomarker. The equilibrium of such static biomarkers could be affected by various factors, including increased protein production and/or secretion, increased protein release in response to a stimulus such as injury or disruption of cellular integrity or defective clearance from the biological fluid. By contrast, SILK provides dynamic measures of protein production and clearance that might provide a more detailed understanding of the actual mechanism or mechanisms underlying these changes in biomarker concentration. CSF tau levels offer a striking example of the advantages of dynamic biomarkers over static biomarkers 30 . The increased CSF tau concentration observed in patients with AD was initially interpreted as resulting from the passive release of this protein by dying neurons 33 . By contrast, results from SILK studies suggest that the bulk of tau in human CSF is released by an active process that is stimulated by neuronal exposure to aggregated Aβ 30 .
Presymptomatic diagnosis
In neurodegenerative diseases characterized by the accumulation of misfolded or otherwise defective proteins, altered production or clearance of a protein might be a trait (that is, lifelong) marker that precedes build-up of the protein in inclusions or aggregates. Informative changes in the turnover of such proteins might occur during the progression of disease that could be monitored using SILK. For example, during the progression of AD and other neurodegenerative diseases, increased secretion of a protein might be followed by a phase of decreased production due to the loss of viable neurons. Similarly, disease-stage-dependent changes in protein clearance could result in altered CSF or plasma concentrations. SILK studies could potentially identify the cause of such changes, and this information could lead to the identification of early biomarkers or drive the development of therapies specifically targeting either production or clearance 32 .
Correcting for interindividual variation
By determining the production and clearance rates of multiple proteins, SILK can assist in understanding normal interindividual differences in protein volume 15 | JulY 2019 | 423 Nature reviews | NeuroLogy P e r s P e c t i v e s concentrations. A number of additional aspects should be explored, such as changes in overall CSF production and clearance rates associated with dysfunction of the choroid plexus 34 or blood-brain barrier 35 , which could affect both CSF biomarker concentrations and SILK data on individual proteins. For example, using SILK studies to measure the production and clearance rates of choroidplexus-derived molecules could potentially lead to the quantitative measurement of CSF dynamics. Furthermore, paired measurements of turnover rates in CSF and blood might yield information about the intrathecal versus peripheral production of a biomolecule.
Measuring target engagement SILK might be useful to confirm target engagement of a new treatment, for example, by detecting alterations in the production rate of a specific protein in CSF or blood in response to a putative diseasemodifying therapy. Such changes in protein kinetics might occur before a change in the steady-state protein concentration is observed 32 . This application of SILK studies is particularly important in neurodegenerative diseases, in which a reservoir of the protein in brain tissue might affect its CSF or plasma concentration. Refined protein turnover measurements might result in increased statistical power (and consequently the need to recruit fewer patients) in clinical trials of new treatments.
Probing synaptic degeneration
Synaptic impairment and synapse loss are early features of neurodegenerative diseases, including AD, that occur before frank neuronal degeneration 36 . This observation has prompted the investigation of synaptic proteins as early-stage biomarkers. Neurogranin, a dendritic protein enriched in neurons, is the best-established CSF biomarker of synapse loss or dysfunction associated with AD [37] [38] [39] . SILK could help to clarify whether increases in the CSF concentration of synaptic markers reflect synaptic degeneration and/or injury or increased marker secretion triggered by the synaptic dysfunction or altered neuronal activity patterns; if the increase in CSF concentration of neurogranin in patients with AD is caused by accelerated biomarker production, levels of labelled protein would rise, whereas if the increase is attributable to the release of pre-existing synaptic proteins from dying synapses, only the level of unlabelled protein would increase.
Probing axonal degeneration
Neurofilament light polypeptide (NFL), a microfilament component of the neuronal cytoskeleton, is a promising protein biomarker of axonal damage in a range of diseases. NFL levels in CSF are elevated in several neurodegenerative diseases 40 and in active neuroinflammation 41 . CSF and serum NFL concentrations are increased after traumatic brain injury (TBI) and peak at 144 h after TBI 42 . This delay could perhaps be explained by a long half-life of NFL. In mice, the results of a single study suggest that the half-life of NFL could be as long as 50 days 42 , but NFL kinetics in human CSF and serum are currently unknown. Therefore, NFL-SILK could be used to elucidate the meaning of these elevated NFL levels -specifically whether such elevations relate to passive release of NFL by damaged axons or upregulated production and secretion of this protein reflecting attempted axonal regeneration. Protein kinetic information is critical to accurately interpret changes in levels of this biomarker and to determine whether an elevated NFL concentration has the same meaning across different neurodegenerative and neuroinflammatory diseases.
Probing neuroinflammation
A substantial body of evidence indicates that neuroinflammation plays an important and early part in neurodegeneration. For example, the genes TREM2 (reF.
43
) and CD33 (reF.
44
) (both of which encode immune receptors) are associated with AD and other neurodegenerative diseases. Triggering receptor expressed on myeloid cells 2 (TREM2) is a type 1 transmembrane protein expressed on the surface of microglia. The ectodomain of TREM2 is proteolytically cleaved and released into the extracellular space as secreted TREM2 (sTREM2), which can be measured in CSF. In patients with AD, CSF levels of sTREM2 increase later than alterations in CSF levels of Aβ or tau, but still before the onset of cognitive symptoms 45 . The function or functions of sTREM2 are unknown, but SILK studies might be able to determine whether the rise in sTREM2 concentration in CSF reflects increased proteolytic cleavage of TREM2 (which would be shown by reduced labelling) or increased production (which would be shown by increased labelling).
Proteomics
Finally, proteins or peptides labelled with stable isotopes can be detected and quantified using non-targeted (shotgun) proteomics. This bottom-up approach relies on the proteolytic digestion of all proteins in a sample followed by separation of the resulting peptides using highperformance liquid chromatography and their identification using tandem MS. With optimal pre-analytic fractionation of the digested peptides, up to 2,630 different proteins can be identified in normal CSF 46 . Preliminary SILK studies, which used LysC or trypsin to digest and fractionate CSF samples followed by quadrupole time-of-flight (Q-TOF) MS, identified a total of 6,398 peptides corresponding to 1,226 proteins 47 . Of these peptides, 4,528 (corresponding to 1,064 proteins) contained leucine and were therefore susceptible to 13 C 6 -leucine labelling. About 10% of the labelled peptides, corresponding to >200 proteins, showed sufficient incorporation of 13 C 6 -leucine to enable the ratio of labelled to unlabelled peptide to be quantified 47 . This capacity of SILK studies to analyse many proteins in parallel can provide information on multiple relevant metabolic and pathophysiological pathways. In addition, by serial analysis of multiple peptides belonging to a single protein, SILK studies can also access the differential behaviours of individual protein domains or features (such as amino-terminal or carboxy-terminal domains) or different isoforms of the same protein (such as ApoE2, ApoE3 and ApoE4).
The analysis of protein kinetics in CSF samples from multiple patients requires a sophisticated bioinformatics pipeline with mathematical modelling to extract different turnover patterns. However, this approach creates an opportunity to discover new dynamic biomarkers, which might be more useful than existing static markers.
Conclusions
SILK is a valuable method for quantifying the rates of production and clearance of specific proteins in vitro and in vivo in different compartments including CSF, blood and brain tissue. If applied to both blood and CSF, SILK studies can also provide relevant information on the movement of proteins between these compartments. Such information can be used to explore the function of the blood-brain barrier and blood-CSF barrier, which is believed to be important in several disorders and neurodegenerative diseases.
To date, SILK studies have determined the turnover rates of Aβ, ApoE, tau and SOD1 in the human CNS and described altered patterns of Aβ and tau metabolism in AD. SILK studies have also shown that sleep deprivation and advanced age influence Aβ clearance. This method volume 15 | JulY 2019 | 425 Nature reviews | NeuroLogy offers the potential to probe other disease pathways in neurodegeneration and may be useful to demonstrate target engagement by putative disease-modifying therapies. Nonetheless, the widespread use of SILK studies in humans is still limited by the high cost of infusion-grade stable isotopes, the availability of suitable MS facilities and the considerable clinical time and effort associated with conducting such studies (Table 1) . However, several important research questions can be addressed only by SILK studies, and sharing clinical and bench protocols as well as resources such as labelled amino acids will help to overcome or mitigate these limitations.
